In treatment naive CLL without del(17p)/TP53, will the recent interim analysis of fixed duration acalabrutinib plus venetoclax +/- obinutuzumab vs chemoimmunotherapy in the AMPLIFY trial change your practice?

Do you recommend fixed duration acalabrutinib plus venetoclax +/- obinutuzumab for treatment naive CLL without del(17p)/TP53 based on AMPLIFY trial?

• Yes, I consider this the new standard of care and will recommend for all patients without high risk cytogenetics
• Yes, I consider this the new standard of care and will recommend for all patients including those with high risk cytogenetics (del(17p)/TP53)
• Possibly, but only in IGHV mutated patients
• Possibly, but only in IGHV un-mutated patients
• Possibly, but only in other patient types (please specify)
• No, I will continue other regimens until formal regulatory approval
• No, I will continue other regimens until longer follow up data is available
• Other